Unity Biotechnology, Inc. (UBX)

NASDAQ: UBX · IEX Real-Time Price · USD
1.92
-0.02 (-1.03%)
Nov 30, 2023, 4:00 PM EST - Market closed
-1.03%
Market Cap 28.07M
Revenue (ttm) n/a
Net Income (ttm) -52.53M
Shares Out 14.62M
EPS (ttm) -3.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 84,534
Open 1.95
Previous Close 1.94
Day's Range 1.92 - 1.99
52-Week Range 1.46 - 5.72
Beta 0.53
Analysts Strong Buy
Price Target 8.40 (+337.5%)
Earnings Date Nov 13, 2023

About UBX

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye d... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 3, 2018
Employees 32
Stock Exchange NASDAQ
Ticker Symbol UBX
Full Company Profile

Financial Performance

In 2022, UBX's revenue was $236,000, a decrease of -95.07% compared to the previous year's $4.78 million. Losses were -$59.93 million, -1.31% less than in 2021.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for UBX stock is "Strong Buy." The 12-month stock price forecast is $8.4, which is an increase of 337.50% from the latest price.

Price Target
$8.4
(337.50% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agi...

17 days ago - GlobeNewsWire

UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or rev...

20 days ago - GlobeNewsWire

UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more ...

2 months ago - GlobeNewsWire

UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agi...

4 months ago - GlobeNewsWire

UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)

Phase 2b trial is a randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 (foselutoclax) compared to aflibercept over 24 weeks

5 months ago - GlobeNewsWire

UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity ( BCVA) of +6.2 ETDRS letters from baseline at 48 weeks

7 months ago - GlobeNewsWire

UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema

Program Update with retinal expert and senior clinical advisor Robert B. Bhisitkul, M.D., Ph.D., to be held on Monday, April 24 at 5:00 a.m. PT/8:00 a.m. ET Program Update with retinal expert and seni...

7 months ago - GlobeNewsWire

UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm

8 months ago - GlobeNewsWire

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ag...

9 months ago - GlobeNewsWire

UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...

9 months ago - GlobeNewsWire

UNITY Biotechnology Reports Granting of New Employment Inducement Award

SOUTH SAN FRANCISCO, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...

11 months ago - GlobeNewsWire

UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates

- Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in...

1 year ago - GlobeNewsWire

UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment

1 year ago - GlobeNewsWire

UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today

UBX common stock expected to begin trading on a split-adjusted basis on October 20, 2022 UBX common stock expected to begin trading on a split-adjusted basis on October 20, 2022

1 year ago - GlobeNewsWire

UNITY Biotechnology's Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye

- Presentations from UNITY's leadership team and fireside chat with retina expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 from 8:00 a.m. to 9:30 a.m. ET -

1 year ago - GlobeNewsWire

UNITY Biotechnology to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, tod...

1 year ago - GlobeNewsWire

UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of a...

1 year ago - GlobeNewsWire

UNITY Biotechnology Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of a...

1 year ago - GlobeNewsWire

UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates

- Announced Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection in subjects led to statistically significant and clinically meaningful improvemen...

1 year ago - GlobeNewsWire

UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

A single injection of UBX1325 led to a progressive, statistically significant, and clinically meaningful improvement in mean Best Corrected Visual Acuity (BCVA) at 12- and 18-weeks compared to sham tr...

1 year ago - GlobeNewsWire

UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME

Investor call with retinal expert Robert Bhisitkul, M.D., Ph.D., to be held on Friday, August 12 at 5:00 a.m. PT/8:00 a.m. ET Investor call with retinal expert Robert Bhisitkul, M.D., Ph.D., to be hel...

1 year ago - GlobeNewsWire

UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...

1 year ago - GlobeNewsWire

UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors

SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today an...

1 year ago - GlobeNewsWire

UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates

-Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME; BEHOLD remains on track with 12-week safety and efficacy data anticipated by mid-year 2022-

1 year ago - GlobeNewsWire

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

Cellular senescence biology in eye disease was a focal point at ARVO opening symposium Cellular senescence biology in eye disease was a focal point at ARVO opening symposium

1 year ago - GlobeNewsWire